Coherus Oncology (CHRS) Gains from Sales and Divestitures (2012 - 2025)
Coherus Oncology recorded quarterly Gains from Sales and Divestitures of $528673.0 in Q4 2025, down 81.08% quarter-over-quarter from $2.8 million in Q4 2024, and down 81.08% year-over-year from $2.8 million in Q4 2024.
Coherus Oncology's Gains from Sales and Divestitures history runs 12 years deep, the most recent figure standing at $528673.0 for Q4 2025.
- In Q4 2025, Gains from Sales and Divestitures fell 81.08% year-over-year to $528673.0; the TTM figure through Dec 2025 stood at $528673.0 (down 81.08% YoY), while the FY2025 annual figure was $528673.0, down 81.08% from the prior year.
- Gains from Sales and Divestitures came in at $528673.0 for Q4 2025 at Coherus Oncology, down from $2.8 million in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $2.8 million in Q4 2024 to a low of $465930.0 in Q4 2021.
- A 5-year average of $1.2 million and a median of $806854.0 in 2022 frame the typical range for Gains from Sales and Divestitures.
- Across the five-year window, Gains from Sales and Divestitures jumped 118.1% in 2024 and slumped 81.08% in 2025, its largest moves.
- Coherus Oncology's Gains from Sales and Divestitures stood at $465930.0 in 2021, then surged by 73.17% to $806854.0 in 2022, then soared by 58.75% to $1.3 million in 2023, then surged by 118.1% to $2.8 million in 2024, then tumbled by 81.08% to $528673.0 in 2025.
- According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $528673.0, $2.8 million, and $1.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Coherus Oncology | 216.87 Mn | 49.83 Mn | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 528,673.00 |
| Dec 31, 2025 | 528,673.00 |
| Dec 31, 2024 | 2.79 Mn |
| Dec 31, 2024 | 2.79 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Dec 31, 2022 | 806,854.00 |
| Dec 31, 2022 | 806,854.00 |
| Dec 31, 2021 | 465,930.00 |
| Dec 31, 2021 | 465,930.00 |
| Dec 31, 2020 | 223,767.00 |
| Dec 31, 2020 | 223,767.00 |
| Dec 31, 2019 | 214,819.00 |
| Dec 31, 2019 | 214,819.00 |
| Dec 31, 2018 | 61,804.00 |
| Dec 31, 2018 | 61,804.00 |
| Dec 31, 2017 | 316,205.00 |
| Dec 31, 2017 | 316,205.00 |
| Dec 31, 2015 | 21,245.00 |
| Dec 31, 2015 | 21,245.00 |
| Dec 31, 2013 | 1.39 Mn |
| Dec 31, 2013 | 1.39 Mn |
| Dec 31, 2012 | 1.21 Mn |
| Dec 31, 2012 | 1.21 Mn |